ReviewCellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology2010
Pulmonary surfactant: an immunological perspective.
Review in Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 211 citations in OpenAlex.
- Valproic acid remodels phosphatidylglycerol homeostasis and epithelial-macrophage crosstalk in inflammatory signaling.iScience · 2026Article
- The dual promise of extracellular vesicles in lung diseases: towards reliable biomarkers and drug delivery vectors.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Adrenergic receptors: a key determinant of outcomes in bacterial pneumonia and bacterial sepsis-associated acute lung injury/acute respiratory distress syndrome through participation in pulmonary innate immune response.Frontiers in immunology · 2026Review
- EGOI-PCOS survey on the prevalence of respiratory disorders associated with polycystic ovary syndrome.Multidisciplinary respiratory medicine · 2025Article
- Pulmonary surfactant-biomimetic membranized coacervate injection for acute respiratory distress syndrome therapy.Acta pharmaceutica Sinica. B · 2025Article
- Age Matters: Key Contributors to Interferon Toxicity in Infants During Influenza Virus Infection.Viruses · 2025Review
- Lung surfactant reducesMicrobiology spectrum · 2025Article
- Generation of induced alveolar assembloids with functional alveolar-like macrophages.Nature communications · 2025Article
- Origin and stepwise evolution of vertebrate lungs.Nature ecology & evolution · 2025Article
- Article
- The Therapeutic Potential of Myo-Inositol in Managing Patients with Respiratory Diseases.International journal of molecular sciences · 2025Review
- The Immune Modulatory Role of Surfactants inJournal of inflammation research · 2025Review
- Immunobiology of pulmonary fibrosis.Frontiers in immunology · 2025Review
- Association between dietary fatty acid intake and preserved ratio impaired spirometry in U.S. adults: a population-based cross-sectional study.Frontiers in nutrition · 2025Article
- Cutting-edge perspectives on biosurfactants: implications for antimicrobial and biomedical applications.3 Biotech · 2024Review
- Association between dietary choline intake and asthma and pulmonary inflammation and lung function: NHANES analysis 2009-2018.Journal of health, population, and nutrition · 2024Article
- Unraveling the enigma: The emerging significance of pulmonary surfactant proteins in predicting, diagnosing, and managing COVID-19.Immunity, inflammation and disease · 2024Review
- Could SP-A and SP-D Serum Levels Predict COVID-19 Severity?International journal of molecular sciences · 2024Article
- Cooperation of immune regulators Tollip and surfactant protein A inhibits influenza A virus infection in mice.Respiratory research · 2024Article
- Effect of nasal carriage ofMicrobiology spectrum · 2024Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Pulmonary surfactant has two crucial roles in respiratory function; first, as a biophysical entity it reduces surface tension at the air water interface, facilitating gas exchange and alveolar stability during breathing, and, second, as an innate component of the lung's immune system it helps maintain sterility and balance immune reactions in the distal airways. Pulmonary surfactant consists of 90% lipids and 10% protein. There are four surfactant proteins named SP-A, SP-B, SP-C, and SP-D; their distinct interactions with surfactant phospholipids are necessary for the ultra-structural organization, stability, metabolism, and lowering of surface tension. In addition, SP-A and SP-D bind pathogens, inflict damage to microbial membranes, and regulate microbial phagocytosis and activation or deactivation of inflammatory responses by alveolar macrophages. SP-A and SP-D, also known as pulmonary collectins, mediate microbial phagocytosis via SP-A and SP-D receptors and the coordinated induction of other innate receptors. Several receptors (SP-R210, CD91/calreticulin, SIRPalpha, and toll-like receptors) mediate the immunological functions of SP-A and SP-D. However, accumulating evidence indicate that SP-B and SP-C and one or more lipid constituents of surfactant share similar immuno-regulatory properties as SP-A and SP-D. The present review discusses current knowledge on the interaction of surfactant with lung innate host defense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.